IMRN
Immuron Limited Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website immuron.com.au
- Employees(FY) 6
- ISIN US45254U1016
Performance
+12.73%
1W
-5.38%
1M
+39.82%
3M
+46.36%
6M
+33.48%
YTD
-6.62%
1Y
Profile
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis of IMRN 2024-05-03
Overview:
In analyzing the technical indicators for IMRN over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-07 19:50
- 2024-05-06 19:00
- 2024-05-06 18:00
Immuron Limited to Present at the Emerging Growth Conference(Globenewswire)
- 2024-05-02 18:00
Immuron Director Resignation(Globenewswire)
- 2024-04-14 18:00
Immuron to host Live Virtual Event(Globenewswire)
- 2024-04-09 18:00
Immuron Travelan sales continued strong growth(Globenewswire)
- 2024-03-06 17:00
- 2024-02-20 17:00
Immuron Presentation Australian Biologics Festival 2024(Globenewswire)
- 2024-02-12 17:00
Immuron achieves record Travelan sales(Globenewswire)
- 2024-02-07 17:00
Immuron CEO, Steven Lydeamore Investor Webinar Presentation(Globenewswire)
- 2024-01-15 17:00
Immuron achieves record half yearly Travelan sales(Globenewswire)
- 2023-12-21 17:00
Immuron Clinical Trials Update(Globenewswire)
- 2023-12-03 17:00
- 2023-11-27 17:33
Immuron CEO, Steven Lydeamore Investor Webinar Presentation(Globenewswire)
- 2023-11-13 05:00
Immuron CEO Steven Lydeamore Investor Webinar Presentation(Globenewswire)
- 2023-10-29 19:21
Immuron CEO Steven Lydeamore presented at AusBioInvest(Globenewswire)
- 2023-10-17 18:00
Immuron Announces Travelan Clinical Study Cohort 2 commences(Globenewswire)
- 2023-10-10 18:00
Immuron achieves record quarterly Travelan sales(Globenewswire)
- 2023-09-17 19:30
- 2023-09-14 01:30
Immuron hails record monthly sales of Travelan(Yahoo Finance)
- 2023-09-12 18:00
Immuron achieves record monthly Travelan® sales(Yahoo Finance)
- 2023-09-10 18:00
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright(Yahoo Finance)
- 2023-08-22 20:30
Planet MicroCap Review Magazine for Summer 2023 Now Online(Yahoo Finance)
- 2023-08-13 18:00
- 2023-07-26 02:45
Immuron welcomes launch of Travelan on Amazon US(Yahoo Finance)
- 2023-07-24 18:00
- 2023-07-23 18:00
Immuron CEO, Steven Lydeamore to present at Bioshares(Yahoo Finance)
- 2023-07-18 20:30
- 2023-07-10 18:00
- 2023-07-04 18:00
Immuron FY23 Sales increase 136% on FY22 Sales(Yahoo Finance)
Page 1 of 3
previousnext